Details for Patent: 12,201,639
✉ Email this page to a colleague
Which drugs does patent 12,201,639 protect, and when does it expire?
Patent 12,201,639 protects AGAMREE and is included in one NDA.
Summary for Patent: 12,201,639
| Title: | Aqueous oral pharmaceutical suspension compositions |
| Abstract: | Provided is an aqueous oral pharmaceutical suspension composition comprising vamorolone Form I. Also provided are methods for its preparation and its use. |
| Inventor(s): | John McCall, Jesse Damsker |
| Assignee: | Reveragen Biopharma Inc |
| Application Number: | US17/809,192 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 12,201,639
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Catalyst Pharms | AGAMREE | vamorolone | SUSPENSION;ORAL | 215239-001 | Oct 26, 2023 | RX | Yes | Yes | 12,201,639 | ⤷ Start Trial | Y | Y | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
